Â
Most people searching for better sleep have tried the obvious options. Melatonin works for some. Magnesium helps others. But for a growing number of adults, neither is enough, and the search continues.
CBN has started appearing in that search more frequently. The conventional explanation for its sleepy reputation was simple: aged cannabis made people drowsy because THC had oxidized into CBN over time. That story is partially correct. CBN does appear to have genuine sedative properties. But the mechanism is more specific, and more interesting, than the folklore suggested, and the research has finally started catching up.
Two bodies of evidence now give CBN's sleep applications firmer scientific grounding: a 2024 polysomnography study from the University of Sydney's Lambert Initiative, the first to use objective sleep measures in an animal model[1], and a randomized, double-blind, placebo-controlled human trial published in Experimental and Clinical Psychopharmacology that found significant reductions in nighttime awakenings at a 20 mg nightly dose[2]. Neither study provides an unequivocal verdict, but they both move the conversation past speculation.
What Is CBN?
CBN, or cannabinol, is a cannabinoid that forms naturally as THC ages and oxidizes. Unlike CBD (cannabidiol) or CBG (cannabigerol), it is not produced in large quantities by the hemp plant directly. It accumulates over time through an oxidative process and decarboxylation, which is why CBN is sometimes found in higher concentrations in older cannabis plant material.
Because it originates from THC, CBN carries a persistent misconception that it is intoxicating. At the concentrations found in hemp-derived products, it is not. CBN is a low-affinity partial agonist at CB1 receptors, the same receptors THC activates. The critical difference is the receptor-cannabinoid affinity: CBN's binding affinity at CB1 is roughly 5 to 10 times weaker than THC's. This means it can engage the receptor, and produce downstream effects including sedation, without the receptor saturation, the intoxication, or the REM suppression associated with full agonism. At supplemental doses, CBN does not produce impairment.
The Folklore Problem: Why CBN's Reputation Ran Ahead of the Evidence
The association between CBN and sedation originated not in controlled research but in the empirical observation that older, poorly stored cannabis tended to produce more body-heavy, drowsy effects. Since THC oxidizes into CBN during prolonged air and light exposure, the logical conclusion was that CBN was causing the sedation. The logic was not wrong. It was just untested.
What complicated the picture: aged cannabis also contains altered terpene profiles, degraded potency across multiple cannabinoids, and a different ratio of emergent minor compounds than fresh cannabis. Attributing the sedation specifically to CBN required isolating it from everything else. That isolation did not happen rigorously until recently.
A 2021 narrative review in Cannabis and Cannabinoid Research[3] found that most pre-2020 human studies on CBN were small, methodologically limited, and not designed to assess sleep outcomes. Preclinical sedation data existed, including a 1974 study showing CBN prolonged barbiturate-induced sleeping time in mice[4], but translation to human sleep physiology remained undemonstrated. The gap between consumer claims and clinical evidence was real. It has narrowed over the past couple decades, but it is not closed.
How CBN Interacts with the Endocannabinoid System (ECS)
CBN's partial agonist profile at CB1 receptors is the foundation of its proposed sleep mechanism. CB1 activation by CBN inhibits adenylyl cyclase, reducing cAMP and modulating neurotransmitter release at presynaptic terminals in a pattern consistent with other cannabinoids, but at considerably lower potency. This is the mechanism that produces sedation without the adverse profile associated with stronger CB1 activation.
CBN also shows greater relative affinity for CB2 receptors, which are found primarily on immune cells and peripheral tissue. The functional contribution of CB2 activity to CBN's sedative effects is not yet established.
One finding from the University of Sydney's 2024 work[1] adds a layer of complexity that most CBN coverage has missed. The primary metabolite of CBN, 11-OH-CBN, appears to have meaningfully stronger CB1 activity than the parent molecule. This suggests that some of the sedative effect attributed to CBN may operate through its secondary metabolic products rather than directly through the compound itself, a distinction with real implications for dosing, onset timing, and formulation strategy.
There is also early evidence that CBN may potentiate GABA activity, the primary inhibitory neurotransmitter in the brain. GABA is associated with reduced neural excitation and is the target of many pharmaceutical sleep aids. If CBN supports GABA signaling, it could help quiet the mental activity that delays sleep onset for people who feel alert at bedtime despite being tired.
The 2024 Polysomnography Study: What Objective Sleep Measures Showed
The University of Sydney's Lambert Initiative published the first polysomnography study of CBN in animal models in November 2024 in Neuropsychopharmacology[1]. Polysomnography, the same EEG-based methodology used in clinical sleep labs, allowed the researchers to track NREM and REM sleep architecture rather than relying on behavioral proxies.
CBN increased both NREM and REM sleep, producing higher total sleep time in a pattern the researchers characterized as comparable to zolpidem, the prescription sleep aid. NREM sleep, associated with physical recovery and memory consolidation, was extended rather than suppressed. REM sleep, linked to emotional processing, was also preserved. This profile is different from what is typically seen with full CB1 agonists, which tend to suppress REM at higher doses, and from benzodiazepines, which are known to alter sleep architecture in ways that compromise sleep quality even as they extend total duration.
The researchers also noted a biphasic effect: an initial period of mild sleep suppression followed by a significant increase. This is not characteristic of conventional sedatives and may be relevant to understanding optimal timing relative to sleep onset.
The findings are confined to rats at this stage. The study was designed as a preclinical foundation for further investigation, not a clinical recommendation. The Lambert Initiative has since initiated a preclinical drug discovery program around CBN and is examining whether the compound's sleep-promoting effects can be amplified in combination with other cannabis constituents or conventional sleep aids.
The Controlled Human Trial: Nighttime Awakenings and Sleep Disturbance
The most rigorous human data published to date comes from a double-blind, randomized, placebo-controlled study conducted across 321 participants who self-rated their sleep quality as poor or very poor, published in Experimental and Clinical Psychopharmacology in 2024 (Bonn-Miller et al.)[2]. Participants received 20 mg CBN nightly for seven consecutive nights.
The primary endpoint, overall sleep quality measured via validated questionnaire, showed a trend favoring CBN over placebo but did not reach statistical significance. Two secondary endpoints did. Nighttime awakenings were significantly reduced in the CBN group compared to placebo (p = .025), as was overall sleep disturbance (p = .023). No significant differences were observed for sleep onset latency. No impact on daytime fatigue was recorded.
Read honestly, the trial supports CBN's utility for sleep maintenance, the ability to stay asleep through the night, more than for sleep initiation. The onset latency data suggests CBN does not meaningfully accelerate falling asleep at 20 mg. What it appears to do is reduce the frequency of awakenings, which is a distinct and clinically relevant problem for a substantial portion of people with poor sleep.
One additional finding: the addition of CBD at doses of 10 mg, 20 mg, or 100 mg did not augment CBN's effects on any measure. This cuts against a common industry framing of CBN and CBD as natural complements for sleep formulation at the doses tested. The sleep mechanism being activated by CBN appears to operate through a pathway that CBD does not amplify.
What a 2025 Meta-Analysis Found About Which Cannabinoids Actually Drive Sleep Improvement
A 2025 systematic review and meta-analysis published in Sleep Medicine Reviews analyzed data from six randomized controlled trials involving 1,077 participants[5]. The finding most relevant to formulation: cannabinoid-based interventions were associated with improved sleep quality, but only when THC or CBN was present. Formulations containing CBD alone did not produce statistically significant improvements in subjective sleep assessments compared to placebo.
This does not mean CBD (such as the targeted dose found in a CBD Protab) has no role in sleep support. It means CBD alone is not sufficient to drive the sleep quality improvements detected in these trials. The data suggests that the partial CB1 agonist activity shared by THC and CBN, operating through a mechanism that CBD does not replicate, is what produces the measurable sleep effect in the populations studied.
The implication is straightforward: CBN's presence in a sleep product is not decorative. It is doing specific mechanistic work that other cannabinoids in the formulation are not.
CBN vs. Melatonin: A Useful Comparison
A separate 2024 randomized, placebo-controlled trial [6] compared three doses of a hemp-derived CBN product against 4 mg melatonin. All three CBN doses and melatonin produced statistically significant improvements in sleep quality compared to placebo, and all three CBN doses were statistically equivalent to melatonin for overall sleep quality improvement.
The comparison is worth reading carefully. Melatonin primarily regulates circadian phase, the timing signal that communicates to the brain when sleep should begin. CBN operates through a different mechanism entirely: partial CB1 engagement, not melatonin receptor agonism. These are not interchangeable pathways. The comparison does not establish that CBN and melatonin are mechanistically equivalent, only that their self-reported sleep quality outcomes were similar at the doses tested.
The practical difference matters. If you fall asleep easily but wake frequently, CBN's proposed mechanisms may be more directly applicable than melatonin's. If your primary issue is trouble initiating sleep, melatonin's circadian-timing mechanism is more specifically relevant. For some people, both issues are present, and using both makes sense.
The Consistency Principle
One of the more consistent findings across cannabinoid sleep research, such as the Bonn-Miller trial[2] which established significance after seven consecutive nights of administration, and patterns noted in recent systematic reviews[5], is that consistency of use matters more than dose. This held true in LEVEL's own observational study conducted in partnership with MoreBetter, which followed 157 participants over 29 days using the SLEEP Protab.
Participants who used LEVEL's SLEEP Protab consistently reported approximately 41 more minutes of sleep per night by day 29, along with a 50% improvement in reported sleep quality, 25% fewer nighttime awakenings, and 25% reduced use of other sleep aids. The only significant moderator of outcomes was consistency, not dose escalation. This is observational data, not a controlled trial, and should be read as such. It is consistent with what the controlled research on CBN predicts: reduced awakenings, improved overall sleep quality, no daytime fatigue burden.
The practical takeaway: if you try CBN once and do not notice a dramatic effect, that is not a signal it is not working. The effect tends to build over a sustained nightly practice. Furthermore, it is important to remember that for the best results, any sleep supplement should be paired with strong sleep hygiene, such as maintaining a consistent bedtime routine, keeping your bedroom cool and dark, and minimizing screen time before bed.
LEVEL's Approach to CBN-Based Sleep Support
The research trajectory on CBN converges on a practical point: CBN's sleep effects appear most reliable for maintenance rather than initiation, and the mechanism operates through partial CB1 engagement, not sedation in the crude pharmacological sense.
LEVEL's NIGHTTIME Tablingual delivers CBN via sublingual absorption, bypassing first-pass hepatic metabolism to reach systemic circulation more rapidly than a swallowed tablet or capsule. The 11-OH-CBN metabolite finding from the Sydney lab[1] suggests the metabolic pathway matters for onset profile, and sublingual delivery provides an alternative to that pathway for users who need faster effect onset. The formulation uses 100% CBN with no melatonin, no added sedatives, and no compounds that carry next-day grogginess risk.
LEVEL's SLEEP Protab is a multi-cannabinoid formulation containing CBD, CBN, CBG, and THCa, built on the premise that precision in composition produces different results than single-compound products. The inclusion of CBN is grounded in the mechanistic case above, not trend-following. THCa contributes TRPV1 and PPARgamma receptor activity without psychoactive CB1 load. CBG (which is also available as a standalone CBG Protab) introduces a distinct receptor interaction profile. Each compound is doing specific work.
If you are new to cannabinoid-based sleep support and want to explore the broader LEVEL range before committing to a single product, the Discovery Kit is designed as an entry point. Our quiz at can also help match you to the right formulation for your specific sleep pattern.
Frequently Asked Questions
Does CBN make you high?
CBN is a low-affinity partial agonist at CB1 receptors, the receptor responsible for THC's psychoactive effects. At the doses used in sleep formulations, CBN does not produce intoxication. The receptor affinity differential between THC and CBN is approximately 5 to 10 times, meaning the dose required for CBN to produce psychoactive effects is far above what appears in commercially available sleep products.
How is CBN different from CBD for sleep?
CBN and CBD operate through distinct mechanisms. CBN acts as a partial CB1 agonist, engaging the receptor directly. CBD does not act as a CB1 agonist, and its sleep-related effects are mediated through different pathways. The 2025 meta-analysis covering six RCTs[5] found that formulations containing CBN (and THC) were associated with statistically significant sleep improvements, while CBD-only formulations were not. They are not equivalent for sleep applications.
What does the research say CBN actually helps with during sleep?
The controlled human trial evidence is strongest for sleep maintenance: specifically, reducing nighttime awakenings and overall sleep disturbance[2]. The effect on sleep onset latency was not statistically significant in the primary controlled trial at 20 mg. Preclinical polysomnography data shows CBN increases both NREM and REM sleep in rats[1], suggesting the sedative effect operates through sleep-stage preservation rather than indiscriminate sedation.
Is CBN safe for regular use?
The controlled human trials published to date, including the 321-participant Bonn-Miller study[2], found only mild side effects and no significant differences in side effect frequency between CBN and placebo groups. No impact on daytime fatigue was observed, which distinguishes CBN from pharmaceutical sleep aids that carry residual sedation. Long-term repeated-dose safety data in humans remains limited. Anyone with concerns about drug interactions or underlying health conditions should consult a healthcare provider.
How does CBN work in a multi-cannabinoid formulation?
The 2025 meta-analysis data[5] suggests multi-cannabinoid formulations that include CBN or THC outperform single-cannabinoid CBD approaches for sleep quality outcomes. LEVEL's SLEEP Protab combines CBN with THCa, CBG, and CBD based on the distinct receptor profiles of each compound. CBN drives the partial CB1 engagement associated with sleep maintenance. THCa contributes TRPV1 and PPARgamma activity. CBG modulates a distinct receptor profile. The formulation reflects a mechanistic rationale, not additive marketing.
References
PEER-REVIEWED SOURCES CITED
[1] Chesworth, R., et al. (2024). Cannabinol (CBN) increases sleep in rodents: Involvement of CB1 receptors and the metabolite 11-OH-CBN. Neuropsychopharmacology. Lambert Initiative for Cannabinoid Therapeutics, University of Sydney. Published November 2024. Link to journal
[2] Bonn-Miller, M.O., et al. (2024). A randomized, double-blind, placebo-controlled study of the effects of cannabinol (CBN) on sleep in adults with self-reported poor sleep quality. Experimental and Clinical Psychopharmacology. https://pubmed.ncbi.nlm.nih.gov/33998874/
[3] Corroon, J. (2021). Cannabinol and sleep: Separating fact from fiction. Cannabis and Cannabinoid Research, 6(5), 366-371. https://pubmed.ncbi.nlm.nih.gov/34468204/
[4] Paton, W.D.M., & Pertwee, R.G. (1974). The pharmacology of cannabis in animals. In L.L. Iversen, S.D. Iversen, & S.H. Snyder (Eds.), Handbook of Psychopharmacology. As cited in Corroon (2021): CBN prolonged barbiturate-induced sleeping time in mice. https://abdn.elsevierpure.com/en/publications/the-pharmacology-of-cannabis-in-animals/
[5] Walsh, J.H., et al. (2025). Cannabinoids and sleep: A systematic review and meta-analysis of randomized controlled trials. Sleep Medicine Reviews. (6 RCTs, n = 1,077 participants.) https://doi.org/10.1016/j.smrv.2025.102164
[6] Winiger, E.A., et al. (2024). Hemp-derived cannabinol (CBN) versus melatonin for sleep: A randomized, double-blind, placebo-controlled trial. [Citation details pending full journal confirmation; study compared three CBN doses against 4 mg melatonin.]
OBSERVATIONAL DATA
MoreBetter / LEVEL Sleep Protab Observational Study. 157 participants, 29 days. Conducted in partnership with MoreBetter. Outcome measures: minutes of sleep, sleep quality rating, nighttime awakenings, use of other sleep aids. Not a randomized controlled trial. Results reflect participant self-report and should not be interpreted as equivalent to peer-reviewed clinical evidence.
